Showing results (51-60 of 68) with videos related to
Sort By:
Pageof 7
Journal of Medicinal Chemistry|November 30, 2004
Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitorsAranapakam M Venkatesan, Jamie M Davis, George T Grosu, et al.Nature Communications|January 3, 2025
Development of small molecule non-covalent coronavirus 3CL protease inhibitors from DNA-encoded chemical library screeningHengrui Liu, Arie Zask, Farhad Forouhar, et al.Biorxiv : the Preprint Server for Biology|September 2, 2020
A simplified cell-based assay to identify coronavirus 3CL protease inhibitorsSamuel J Resnick, Sho Iketani, Seo Jung Hong, et al.Journal of Medicinal Chemistry|May 30, 2003
Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritisVenkatesan Aranapakam, George T Grosu, Jamie M Davis, et al.Journal of Medicinal Chemistry|March 26, 2009
Discovery of 4-(benzylaminomethylene)isoquinoline-1,3-(2H,4H)-diones and 4-[(pyridylmethyl)aminomethylene]isoquinoline-1,3-(2H,4H)-diones as potent and selective inhibitors of the cyclin-dependent kinase 4Hwei-Ru Tsou, Xiaoxiang Liu, Gary Birnberg, et al.Journal of Medicinal Chemistry|November 10, 2009
Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituentJeroen C Verheijen, David J Richard, Kevin Curran, et al.Cancer Discovery|August 19, 2022
Pharmacologic Inhibition of NT5C2 Reverses Genetic and Nongenetic Drivers of 6-MP Resistance in Acute Lymphoblastic LeukemiaClara Reglero, Chelsea L Dieck, Arie Zask, et al.Cancer Biology & Therapy|April 23, 2005
PWT-458, a novel pegylated-17-hydroxywortmannin, inhibits phosphatidylinositol 3-kinase signaling and suppresses growth of solid tumorsKer Yu, Judy Lucas, Tianmin Zhu, et al.Journal of Medicinal Chemistry|October 24, 2009
Discovery of potent and selective inhibitors of the mammalian target of rapamycin (mTOR) kinasePawel Nowak, Derek C Cole, Natasja Brooijmans, et al.Cancer Research|April 19, 2003
HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivoFrank Loganzo, Carolyn M Discafani, Tami Annable, et al.Pageof 7